Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis

• Peng Ye ,

  Contributed equally to this work with: Peng Ye, Meizhuo Zhang

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Meizhuo Zhang ,

  Contributed equally to this work with: Peng Ye, Meizhuo Zhang

  Affiliation Research & Development Information, AstraZeneca R&D, Shanghai, China

  ⨯
• Shuqiong Fan,

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Tianwei Zhang,

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Haihua Fu,

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Xinying Su,

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Paul R. Gavine,

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯
• Qiang Liu ,

  * E-mail: lucy.yin@astrazeneca.com (XY); liuq1963@sohu.com (QL)

  Affiliation Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

  ⨯
• Xiaolu Yin

  * E-mail: lucy.yin@astrazeneca.com (XY); liuq1963@sohu.com (QL)

  Affiliation Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China

  ⨯